Video

Alasdair Coles, MD

Publish date: May 7, 2015

Prof. Coles provides four-year follow-up data from the CARE-MS I and CARE-MS II trials, which showed the durable effect of alemtuzumab.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Switch to Oral Fingolimod May Improve MS Outcomes
ICYMI Multiple Sclerosis
Conference News Update—Federation of American Societies for Experimental Biology
ICYMI Multiple Sclerosis
Can FLAIR MRI Show Treatment Efficacy?
ICYMI Multiple Sclerosis
Using the GAD-7 Scale in Multiple Sclerosis Patients
ICYMI Multiple Sclerosis
Concurrent Autoimmune Diseases in MS
ICYMI Multiple Sclerosis
Does Pharmacy-Directed Treatment Management Improve Care?
ICYMI Multiple Sclerosis
MSC Consensus Paper on DMTs in MS
ICYMI Multiple Sclerosis
Robert Fox, MD
ICYMI Multiple Sclerosis
Stacey Cofield, PhD
ICYMI Multiple Sclerosis
Amber Salter, PhD, MPH
ICYMI Multiple Sclerosis